Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization

Ameya S. Kulkarni, Sandra Aleksic, David M. Berger, Felipe Sierra, George A Kuchel, Nir Barzilai

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Common chronic diseases represent the greatest driver of rising healthcare costs, as well as declining function, independence, and quality of life. Geroscience-guided approaches seek to delay the onset and progression of multiple chronic conditions by targeting fundamental biological pathways of aging. This approach is more likely to improve overall health and function in old age than treating individual diseases, by addressing aging the largest and mostly ignored risk factor for the leading causes of morbidity in older adults. Nevertheless, challenges in repurposing existing and moving newly discovered interventions from the bench to clinical care have impeded the progress of this potentially transformational paradigm shift. In this article, we propose the creation of a standardized process for evaluating FDA-approved medications for their geroscience potential. Criteria for systematically evaluating the existing literature that spans from animal models to human studies will permit the prioritization of efforts and financial investments for translating geroscience and allow immediate progress on the design of the next Targeting Aging with MEtformin (TAME)-like study involving such candidate gerotherapeutics.

Original languageEnglish (US)
Article numbere13596
JournalAging cell
Volume21
Issue number4
DOIs
StatePublished - Apr 2022

Keywords

  • aging
  • clinical trials
  • drug repurposing
  • geroscience
  • preclinical studies

ASJC Scopus subject areas

  • Aging
  • Cell Biology

Fingerprint

Dive into the research topics of 'Geroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization'. Together they form a unique fingerprint.

Cite this